Aandelen in “Farmaceutische Producten: Generisch”

Aandeel Datum Koers Evolutie
vlag Teva- Pharmaceutical Industries Ltd. 12/12 29,790 USD
-1,29% 		-1,29%
vlag TherapeuticsMD Inc 12/12 1,750 USD
-4,89% 		-4,89%

Nieuws over “Farmaceutische Producten: Generisch”

12/12 · Teva Releases Q4 2025 Aide Memoire · Persbericht

12/12 · Teva Releases Q4 2025 Aide Memoire · Persbericht

12/12 · Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 · Persbericht

9/12 · Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults · Persbericht

8/12 · Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US · Persbericht

25/11 · Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® · Persbericht

21/11 · Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December · Persbericht

19/11 · Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges · Persbericht

8/11 · AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living · Persbericht

5/11 · Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS · Persbericht

3/11 · Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis · Persbericht

31/10 · Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November · Persbericht

20/10 · Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe · Persbericht

10/10 · FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder · Persbericht

1/10 · Europese Commissie opent mededingingsonderzoek naar griepvaccins bij Sanofi · Bolero.be

Sanofi bevestigt dat de Europese mededingingsautoriteiten invallen hebben gedaan in kantoren in Frankrijk en Duitsland. De Europese Commissie onderzoekt mogelijke misleidende communicatie over concurrenten in de griepvaccinmarkt,...

25/09 · Teva Releases Q3 2025 Aide Memoire · Persbericht

25/09 · Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025 · Persbericht

21/09 · Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction · Persbericht

21/09 · New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed · Persbericht

16/09 · Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting · Persbericht

Mijn selecties